Phaserx Inc. (PZRXQ)

Overview

PhaseRx, Inc. is a pioneering biopharmaceutical enterprise focusing on the advancement of a suite of products aimed at the therapeutic management of inherited enzymatic deficiencies affecting the liver. This endeavor is centered around the revolutionary use of intracellular enzyme replacement therapy. Utilizing its proprietary Hybrid mRNA technology platform, PhaseRx is adept at engineering therapies that facilitate the internal synthesis of otherwise absent enzymes within cells, targeting a direct approach to treatment at a molecular level. Since its establishment in 2006, the company has been steadfast in its mission to innovate within the biopharmaceutical sector, proudly anchoring its operations in Seattle, Washington.

Products and Services

PRX-OTC: This flagship product by PhaseRx stands as a novel therapeutic offering intended for the treatment of ornithine transcarbamylase deficiency. Through the leveraging of PhaseRx’s Hybrid mRNA technology, PRX-OTC aims to rectify this genetic disorder by enabling the affected cells to produce the OTC enzyme, which is crucial for a functioning urea cycle and thereby mitigating the detrimental accumulation of ammonia in the bloodstream.

PRX-ASL: Tailored to address argininosuccinate lyase deficiency, PRX-ASL symbolizes an innovative therapeutic approach within PhaseRx’s product pipeline. By intervening at a cellular level, it attempts to correct the deficiency by facilitating the synthesis of the ASL enzyme directly inside liver cells. This strategic application seeks to restore the critical urea cycle process, ultimately reducing harmful substances from the body and offering a beacon of hope for patients grappling with this rare metabolic condition.

PRX-ASS1: Aimed at combatting argininosuccinate synthetase deficiency, PRX-ASS1 is another key contender among PhaseRx’s therapeutic developments. Utilizing the same pioneering technology, this treatment focuses on replenishing the deficient ASS1 enzyme within the liver cells of affected individuals. By doing so, it strives to normalize the urea cycle, promoting the detoxification of ammonia and offering a promising avenue towards managing this challenging genetic disorder.